Ladenburg Thalmann & Co. Remains a Buy on Eiger Biopharmaceuticals (EIGR)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGRResearch Report), with a price target of $28.00. The company’s shares opened today at $7.07.

According to TipRanks, Higgins is a 4-star analyst with an average return of 6.7% and a 31.87% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Eiger Biopharmaceuticals, and Astria Therapeutics.

Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $10.02 and a one-year low of $3.53. Currently, Eiger Biopharmaceuticals has an average volume of 300.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Read More on EIGR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More